ProPhase Labs Inc. to Present Third Quarter 2024 Financial Results on November 13, 2024
ProPhase Labs (NASDAQ: PRPH), a biotech, genomics and diagnostics company, announced it will present its third quarter 2024 financial results via a virtual conference call on November 13, 2024 at 11:00 AM EST. The call will be hosted by Renmark Financial. A press release with detailed results will be issued before the call. Stakeholders and investors can register to attend the live event, with a replay available afterward on the company's investor website.
ProPhase Labs (NASDAQ: PRPH), una società di biotecnologie, genomica e diagnostica, ha annunciato che presenterà i suoi risultati finanziari per il terzo trimestre del 2024 tramite una conferenza telefonica virtuale il 13 novembre 2024 alle 11:00 AM EST. La chiamata sarà ospitata da Renmark Financial. Un comunicato stampa con i risultati dettagliati sarà pubblicato prima della chiamata. I sostenitori e gli investitori possono registrarsi per partecipare all'evento dal vivo, con una registrazione disponibile successivamente sul sito web per gli investitori della società.
ProPhase Labs (NASDAQ: PRPH), una empresa de biotecnología, genómica y diagnósticos, anunció que presentará sus resultados financieros del tercer trimestre de 2024 a través de una llamada de conferencia virtual el 13 de noviembre de 2024 a las 11:00 AM EST. La llamada será moderada por Renmark Financial. Se emitirá un comunicado de prensa con los resultados detallados antes de la llamada. Los interesados y los inversores pueden registrarse para asistir al evento en vivo, con una repetición disponible posteriormente en el sitio web de inversores de la empresa.
ProPhase Labs (NASDAQ: PRPH)는 생명공학, 유전체학 및 진단 회사로, 2024년 3분기 재무 결과를 가상 컨퍼런스 콜을 통해 2024년 11월 13일 오전 11:00 EST에 발표할 것이라고 발표했습니다. 이 통화는 Renmark Financial이 주최합니다. 발표 전에 자세한 결과를 포함한 보도 자료가 발송될 예정입니다. 이해관계자 및 투자자는 생중계 이벤트에 참석하기 위해 등록할 수 있으며, 회사의 투자자 웹사이트에서 이후 다시 볼 수 있는 옵션이 제공됩니다.
ProPhase Labs (NASDAQ: PRPH), une entreprise de biotechnologie, de génomique et de diagnostic, a annoncé qu'elle présentera ses résultats financiers du troisième trimestre 2024 lors d'une conférence téléphonique virtuelle le 13 novembre 2024 à 11h00 EST. L'appel sera animé par Renmark Financial. Un communiqué de presse avec les résultats détaillés sera publié avant l'appel. Les parties prenantes et les investisseurs peuvent s'inscrire pour assister à l'événement en direct, avec un replay disponible par la suite sur le site web des investisseurs de l'entreprise.
ProPhase Labs (NASDAQ: PRPH), ein Unternehmen für Biotechnologie, Genomik und Diagnostik, hat angekündigt, seine Finanzergebnisse für das dritte Quartal 2024 über eine virtuelle Telefonkonferenz am 13. November 2024 um 11:00 Uhr EST zu präsentieren. Die Konferenz wird von Renmark Financial moderiert. Eine Pressemitteilung mit detaillierten Ergebnissen wird vor der Konferenz veröffentlicht. Interessierte und Investoren können sich registrieren, um an der Live-Veranstaltung teilzunehmen, wobei im Anschluss eine Wiederholung auf der Investorenseite des Unternehmens verfügbar sein wird.
- None.
- None.
GARDEN CITY, NY, Nov. 11, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”), a next generation biotech, genomics and diagnostics company, today announced that they will be presenting third quarter 2024 financial results on a virtual conference call hosted by Renmark Financial on November 13, 2024 at 11:00 AM EST. A press release detailing these results will be issued prior to the virtual conference call. ProPhase Labs Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live event.
Investors interested in participating in this live event will need to register using the link below. After the event, a replay will be available on the company’s investor website.
REGISTER HERE: https://www.renmarkfinancial.com/events/third-quarter-2024-results-virtual-conference-call-nasdaq-prph-B7BiIzlRxh
- To ensure smooth connectivity, please access this link using the latest version of Google Chrome.
About ProPhase Labs
ProPhase Labs Inc. (Nasdaq: PRPH) (“ProPhase”) is a next-generation biotech, genomics and diagnostics company. Our goal is to create a healthier world with bold action and the power of insight. We believe we’re revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions, while developing potential game changer diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Our world-class CLIA labs and cutting-edge diagnostic technology provide wellness solutions for healthcare providers and consumers. We develop, manufacture, and commercialize health and wellness solutions to enable people to live their best lives. We are committed to executional excellence, smart diversification, and a synergistic, omni-channel approach. ProPhase Labs’ subsidiaries and their strategic synergies highlight our potential for long-term value.
Media Relations and Institutional Investor Contact:
ProPhase Labs, Inc.
267-880-1111
investorrelations@prophaselabs.com
Retail Investor Relations Contact:
Renmark Financial Communications
John Boidman
212-812-7680
Jboidman@renmarkfinancial.com
Source: ProPhase Labs, Inc.
FAQ
When will ProPhase Labs (PRPH) report Q3 2024 earnings?
How can investors join ProPhase Labs (PRPH) Q3 2024 earnings call?
Will there be a replay available for ProPhase Labs (PRPH) Q3 2024 earnings call?
